Meloxicam (Metacam) - SHORT-TERM only

Meloxicam, commonly known by the brand name Metacam, is a nonsteroidal anti-inflammatory drug (NSAID) that requires extremely careful consideration in cats due to this species' unique sensitivity to NSAID toxicity. In the United States, meloxicam is FDA-approved for cats only as a single, one-time injection for post-surgical pain control. This critical distinction from canine use reflects the significant safety concerns associated with repeated NSAID administration in feline patients. While some veterinarians may prescribe off-label short-term oral use in specific situations under careful monitoring, cat owners must understand that this medication carries substantial risks in cats that do not exist to the same degree in dogs.

Meloxicam works by inhibiting cyclooxygenase enzymes (primarily COX-2) involved in the production of prostaglandins, which are chemical messengers that promote inflammation, pain, and fever. By reducing prostaglandin synthesis, meloxicam decreases inflammation and provides analgesic effects. However, prostaglandins also play essential protective roles in maintaining kidney blood flow and protecting the gastrointestinal lining, functions that are particularly critical in cats. The feline species lacks certain metabolic pathways present in other animals, making cats significantly more susceptible to the adverse effects of prostaglandin suppression.

Meloxicam is available in both injectable and oral formulations, though their appropriate use in cats differs dramatically from dogs. The injectable formulation is approved for single-dose administration in cats undergoing surgery or experiencing acute pain. The oral suspension, while widely used in dogs for ongoing pain management, carries black box warnings for cats in several countries, including explicit contraindication for repeated dosing in the United States. When oral meloxicam is prescribed for short-term feline use, doses are substantially lower than canine doses and are given only under strict veterinary supervision with careful patient selection.

Understanding the risks associated with meloxicam in cats is essential for any owner whose cat may receive this medication. The drug's benefits for short-term pain control must be weighed against significant risks of kidney injury, gastrointestinal ulceration, and other serious adverse effects. Cats with any pre-existing kidney disease, dehydration, concurrent medication use, or other risk factors face greatly elevated dangers from NSAID therapy. This medication should only be used when a veterinarian has determined it is appropriate for a specific patient in a specific situation, with ongoing monitoring and strict adherence to the prescribed short duration of treatment.

The primary approved indication for meloxicam in cats in the United States is a single subcutaneous injection for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration. This one-time use is the only FDA-approved application of meloxicam in feline patients in the US market, reflecting regulatory recognition of the significant safety concerns with repeated dosing. Veterinary anesthesiologists and surgeons routinely include meloxicam injection as part of multimodal perioperative pain management protocols, where a single dose provides meaningful pain relief during the critical post-surgical recovery period.

Off-label short-term oral use of meloxicam may be prescribed by veterinarians in select situations where the benefits of pain control are judged to outweigh the risks for a specific patient. This might include short courses of several days for acute musculoskeletal pain, post-procedural pain when the injectable form was not given, or other acute painful conditions requiring anti-inflammatory treatment. Such prescriptions represent informed clinical decisions based on individual patient assessment and should always involve thorough discussion with the cat's owner about risks, monitoring requirements, and warning signs. Short-term is typically defined as a few days rather than weeks or months.

In some countries outside the United States, meloxicam oral suspension carries different labeling that may permit longer-term use in cats, though even in these regions, veterinary guidance emphasizes lowest effective doses and careful patient selection. European guidelines, for example, have described protocols for long-term use in cats with osteoarthritis, though this remains controversial and subject to ongoing evaluation. Regardless of regional labeling, the feline sensitivity to NSAID toxicity remains the same, and prolonged use carries risks that many veterinarians consider unacceptable for most patients.

Meloxicam is generally not appropriate for chronic pain management in cats due to cumulative toxicity risks with ongoing administration. Cats requiring long-term pain control for conditions such as osteoarthritis are typically better served by alternative approaches including gabapentin, amitriptyline, physical therapy, weight management, environmental modification, and other non-NSAID strategies. Joint supplements containing glucosamine, chondroitin, or omega fatty acids may provide supportive benefit without NSAID-associated risks. The recent approval of the monoclonal antibody therapy for feline osteoarthritis pain has provided a much safer option for chronic pain management in cats.

When selecting pain management strategies for cats, veterinarians consider the nature and duration of the painful condition, individual patient risk factors, available alternatives, and owner ability to monitor for adverse effects. Meloxicam may be the best choice for short-term acute pain in healthy, well-hydrated cats with normal kidney function when rapid anti-inflammatory effect is needed. However, the medication is not appropriate for cats with kidney disease, dehydration risk, concurrent medications that affect the kidneys, or situations requiring more than a few days of treatment.

Dosing of meloxicam in cats requires extreme precision and must be determined by a veterinarian with full knowledge of the individual patient's health status. Feline doses are dramatically lower than canine doses on both a milligram-per-kilogram and absolute milligram basis, reflecting cats' heightened sensitivity to NSAID toxicity. Using canine dosing in cats or failing to account for feline-specific requirements can result in serious injury or death. Cat owners should never administer meloxicam without explicit veterinary prescription and should never give their cat meloxicam prescribed for a dog or obtained from non-veterinary sources.

The FDA-approved single injection dose for cats undergoing surgery is 0.3 mg/kg administered subcutaneously. This one-time dose is typically given at the time of surgery or during the immediate postoperative period. No repeat injections are approved, and the injectable formulation is not intended for ongoing home use. When veterinarians prescribe off-label oral meloxicam for short-term use, doses are substantially lower, typically starting around 0.05 mg/kg once daily or less, though protocols vary and must be individualized. The specialized veterinary oral suspension formulation allows for the precise small doses required in cats.

Treatment duration with meloxicam in cats should be strictly limited to the shortest time necessary to manage acute pain, typically one to three days for oral use beyond the initial injection. Extended courses are generally avoided due to cumulative toxicity risk. Veterinarians prescribing short-term oral meloxicam typically schedule reassessment within a few days to evaluate whether continued treatment is warranted and whether the cat is tolerating therapy. The medication should be discontinued if pain has resolved, if adverse effects develop, or if the initially planned short course is complete.

Administering oral meloxicam to cats requires careful technique to ensure accurate dosing. The veterinary oral suspension comes with a calibrated dosing syringe that must be used rather than household measuring devices. The medication can be given directly into the mouth or mixed with a small amount of food. It should be given with food to reduce gastrointestinal irritation. Owners must shake the suspension gently before each use to ensure uniform drug distribution. Never guess at doses or use syringes from other products, as even small dosing errors can have significant consequences in cats.

Missed doses of meloxicam during a short-term course should generally be skipped rather than doubled, and the veterinarian should be consulted if doses are missed. Given the short treatment duration typical for appropriate feline use, missing doses may mean the treatment course should simply be concluded. Never give extra doses to make up for missed ones, as this increases toxicity risk. If you are unable to give the medication as prescribed, contact your veterinarian for guidance rather than attempting to adjust the treatment on your own.

Discontinuing meloxicam at the end of the prescribed course does not require tapering for short-term use, unlike some other medications. However, the decision to stop should align with veterinary recommendations rather than owner judgment about whether the cat still seems painful. If pain appears ongoing beyond the safe treatment window, alternative management strategies should be discussed with the veterinarian. Never continue meloxicam beyond the prescribed duration, regardless of pain status, without explicit veterinary approval and understanding of the risks involved.

Meloxicam carries significant risk of serious adverse effects in cats, making close monitoring essential during any treatment course. Unlike in dogs, where meloxicam is generally well-tolerated for extended periods, cats' unique physiology makes them highly vulnerable to NSAID toxicity. The adverse effects of meloxicam in cats can be severe and potentially fatal, which is why the medication carries such restrictive labeling for feline patients. Every cat receiving meloxicam should be considered at risk, and owners must be vigilant for early warning signs throughout treatment.

Kidney injury represents the most serious concern with meloxicam use in cats. NSAIDs reduce prostaglandin-mediated blood flow to the kidneys, which can precipitate acute kidney injury even in cats with previously normal renal function. Cats with any degree of pre-existing kidney disease, even subclinical disease detectable only on laboratory testing, face dramatically elevated risk. Signs of kidney problems may include decreased appetite, increased thirst and urination, vomiting, lethargy, and reduced urine production. Kidney damage from NSAIDs can be irreversible and may significantly shorten a cat's life or prove fatal.

Gastrointestinal effects are another major concern with meloxicam in cats. The medication can cause stomach and intestinal ulceration, which may result in vomiting (possibly with blood), dark or bloody stools, abdominal pain, and loss of appetite. Gastrointestinal perforation, while rare, represents a life-threatening complication. Cats may show subtle signs of gastrointestinal distress such as decreased food interest, excessive salivation, or reluctance to move before more obvious symptoms develop. Providing meloxicam with food may reduce but does not eliminate gastrointestinal risk.

Other serious potential side effects include liver toxicity, blood clotting abnormalities, and systemic effects from prostaglandin suppression. Liver problems may manifest as jaundice (yellowing of gums and whites of eyes), further appetite loss, or changes in behavior. Bleeding problems could present as unexpected bruising, prolonged bleeding from minor wounds, or blood in urine or stool. Any sudden change in your cat's condition during meloxicam treatment should be taken seriously and reported to your veterinarian immediately.

Even when serious complications do not occur, some cats may experience mild adverse effects such as temporary appetite reduction, lethargy, or soft stool during short-term meloxicam treatment. These effects may resolve on their own but should still be communicated to your veterinarian, as they may indicate developing problems or suggest the medication should be discontinued. The absence of obvious side effects does not guarantee safety, as kidney damage can progress without external signs until significant injury has occurred. This reality underscores the importance of limiting treatment duration and avoiding meloxicam in cats with any risk factors for NSAID toxicity.

Meloxicam is absolutely contraindicated in cats with any evidence of kidney disease or impaired renal function, which immediately excludes a substantial portion of the middle-aged and senior cat population. Chronic kidney disease is extremely common in cats, and even early-stage disease that may not be causing clinical signs significantly increases the risk of NSAID-induced kidney injury. Pre-treatment blood work to assess kidney function is strongly recommended before meloxicam administration, and any elevation in kidney values typically precludes use. Cats with a history of kidney disease, even if currently stable, should not receive meloxicam.

Dehydration or any condition predisposing to dehydration represents another critical contraindication for meloxicam in cats. Dehydrated cats have compromised kidney blood flow that NSAIDs will further reduce, potentially precipitating acute kidney failure. Cats that have been vomiting, have diarrhea, have not been eating or drinking normally, or are recovering from illness should not receive meloxicam until fully rehydrated and stable. Even surgical patients, who may have had water withheld pre-operatively, should have their hydration status addressed before NSAID administration.

Concurrent use of other medications that affect the kidneys or gastrointestinal tract creates unacceptable risk when combined with meloxicam. Other NSAIDs should never be given concurrently, and appropriate washout periods must be observed when switching between different NSAIDs. Corticosteroids and meloxicam should not be combined due to dramatically increased risk of gastrointestinal ulceration. Certain antibiotics, diuretics, ACE inhibitors, and other medications affecting kidney function may also be problematic in combination. A complete medication history, including any drugs given in the preceding weeks, is essential before meloxicam can be safely prescribed.

Pre-existing gastrointestinal disease, including history of ulcers, inflammatory bowel disease, or chronic vomiting, contraindicates meloxicam use due to the drug's potential to worsen these conditions. Liver disease similarly increases risk and generally precludes NSAID therapy. Bleeding disorders or concurrent anticoagulant therapy creates risk of hemorrhage. Very young kittens, pregnant or nursing queens, and severely debilitated cats of any age should not receive meloxicam. Essentially, any condition that could be worsened by prostaglandin suppression or that reduces the body's resilience to drug-induced injury argues against meloxicam use.

Complete disclosure of all medications, supplements, and products your cat receives is critically important before meloxicam is prescribed, as numerous dangerous interactions can occur. The consequences of drug interactions with meloxicam in cats can be severe and even fatal, making this one of the most important aspects of safe prescribing. Veterinarians rely on accurate and complete medication histories to identify contraindicated combinations and protect patients from preventable harm.

The combination of meloxicam with corticosteroids (such as prednisolone, dexamethasone, or methylprednisolone) is particularly dangerous and should never occur. This combination dramatically increases the risk of gastrointestinal ulceration and perforation, which can be rapidly fatal. A washout period is required when transitioning between corticosteroids and NSAIDs, with guidelines typically recommending several days to weeks depending on the specific drugs and dosing. If your cat has received any corticosteroid recently, even a single injection, inform your veterinarian before any NSAID is considered.

Other NSAIDs must never be given concurrently with meloxicam, and appropriate washout periods must be observed when switching between different NSAID medications. This includes both prescription NSAIDs and over-the-counter products such as aspirin or ibuprofen (which should never be given to cats under any circumstances). The additive toxicity of multiple NSAIDs can cause rapid onset of severe gastrointestinal or renal damage. If another veterinarian or emergency clinic prescribes an NSAID, ensure they know about any prior meloxicam administration.

Medications affecting kidney function may interact with meloxicam to increase nephrotoxicity risk. Aminoglycoside antibiotics, certain chemotherapy agents, diuretics, ACE inhibitors, and other nephrotoxic drugs create additive or synergistic risk when combined with NSAIDs. Some contrast agents used for imaging procedures can also affect kidney function. Certain heart medications and blood pressure drugs may have their effects altered by concurrent NSAID use. Any medication that affects blood clotting, including aspirin (even baby aspirin), warfarin, or heparin products, creates increased bleeding risk when combined with meloxicam.

The overarching precaution for meloxicam use in cats is recognition that this species is uniquely vulnerable to NSAID toxicity in ways that do not apply to dogs or other animals. Cats lack certain glucuronidation pathways present in other species, resulting in dramatically prolonged drug half-life and increased susceptibility to adverse effects. This fundamental physiological difference means that dosing, duration, and safety considerations for cats are completely different from those for other species. Cat owners must understand that meloxicam for cats is not simply a smaller dose of the canine product but a fundamentally different risk-benefit calculation.

Pre-treatment evaluation is essential before any meloxicam administration in cats. Bloodwork to assess kidney and liver function helps identify cats at elevated risk who should not receive the medication. Hydration status must be normal before dosing. A thorough medication history identifies potentially dangerous interactions. Discussion of the cat's overall health, age, and any concurrent conditions allows informed decision-making about whether meloxicam's benefits outweigh its risks for the individual patient. Emergency or surgical situations may limit pre-treatment workup, but these limitations should be recognized and post-treatment monitoring enhanced accordingly.

Monitoring during meloxicam treatment requires vigilant observation for any changes in the cat's condition. Watch for decreased appetite, vomiting, diarrhea, changes in drinking or urination habits, lethargy, abdominal discomfort, or any other deviation from normal. Because kidney damage can progress without obvious signs, monitoring alone cannot guarantee safety, which is why treatment duration must be limited. If any concerns arise during treatment, contact your veterinarian immediately and discontinue medication pending guidance. Do not wait to see if symptoms worsen before seeking advice.

Post-treatment monitoring may include follow-up bloodwork to assess kidney function after meloxicam administration, particularly for cats receiving more than a single dose. Changes in kidney values detected after treatment may indicate drug-induced injury requiring intervention. Even cats that appear clinically normal may have laboratory evidence of kidney impact. Your veterinarian will advise whether follow-up testing is warranted based on your cat's individual risk factors and treatment course.

Special caution applies to geriatric cats, who often have some degree of subclinical kidney disease even when appearing healthy and having normal behavior. Senior cats represent the population most likely to need pain management but also most likely to be harmed by NSAID therapy. Extremely conservative approaches are warranted for any older cat receiving meloxicam, including pre-treatment bloodwork, lowest effective doses, shortest possible duration, and enhanced monitoring. Alternative pain management strategies should be considered first for most geriatric cats.

Proper storage of meloxicam maintains medication effectiveness and prevents degradation that could alter drug potency or safety. The oral suspension should be stored at controlled room temperature, typically between 59 and 86 degrees Fahrenheit (15 to 30 degrees Celsius), and protected from light. Keep the bottle tightly closed when not in use. Do not freeze the oral suspension. Store in a location away from heat sources, direct sunlight, and areas of high humidity. The injectable formulation has its own storage requirements specified by the manufacturer and is typically retained and used by veterinary clinics rather than dispensed for home use.

Handling the oral suspension requires attention to accurate dosing and preventing contamination. Use only the calibrated dosing syringe provided with the product or supplied by your pharmacy, as household measuring devices are inaccurate and could result in significant over- or underdosing. Shake the bottle gently before withdrawing each dose to ensure uniform drug distribution throughout the suspension. Do not allow the syringe tip to touch surfaces that could introduce contamination into the bottle. Rinse the syringe with water after each use to prevent medication buildup that could affect subsequent dose accuracy.

Safe storage practices protect both household members and pets from accidental exposure. Store meloxicam securely where children and other animals cannot access it. NSAID ingestion by children can cause serious toxicity, and accidental additional doses to your cat or consumption by other pets could cause severe harm. Never transfer meloxicam to unlabeled containers or mix it with other medications. If accidental ingestion by a person or pet occurs, contact poison control or seek immediate medical or veterinary care. Dispose of unused medication properly through a drug take-back program or according to veterinary guidance rather than keeping it for future use, as the strict indication requirements mean leftover medication should not be used without fresh veterinary evaluation.

The extreme caution required for meloxicam use in cats applies universally across all breeds, as the feline species-specific vulnerability to NSAID toxicity is not breed-dependent. Domestic shorthairs, domestic longhairs, and purebred cats of all backgrounds share the metabolic characteristics that make cats uniquely sensitive to meloxicam and other NSAIDs. No cat breed can be considered safe for extended NSAID therapy, and the same restrictive guidelines apply regardless of breed background. Individual patient factors beyond breed determine the risk-benefit calculation for any specific cat.

Certain purebred cats may have genetic predispositions to conditions that further increase meloxicam risk, though these represent additive factors rather than breed-specific drug sensitivities. Breeds with higher incidences of polycystic kidney disease (such as Persians and related breeds) may have compromised renal function that contraindicates NSAID use. Breeds predisposed to hypertrophic cardiomyopathy may be at increased risk if concurrent cardiac medication use is required. These considerations relate to underlying disease prevalence rather than different responses to the drug itself.

Size variation across cat breeds affects dosing calculations, emphasizing the critical importance of accurate weight-based dosing for this high-risk medication. Larger breeds such as Maine Coons require appropriately calculated doses that account for their greater body mass, while smaller breeds need precise measurement of the tiny doses appropriate for cats. Regardless of size, the doses used in cats are far below those used in dogs of similar weight. Using the calibrated syringe provided with the feline oral suspension helps ensure accuracy across all patient sizes.

Age considerations apply across all breeds and significantly impact meloxicam safety in cats. Kittens have developing organ systems and should not receive meloxicam except in specific circumstances under direct veterinary supervision. Senior cats of all breeds face elevated risk due to the high prevalence of subclinical kidney disease in aging felines. Middle-aged and older cats may appear healthy while harboring early kidney changes that dramatically increase NSAID toxicity risk. Pre-treatment screening becomes increasingly important as cats age, regardless of their breed background.

Several alternative medications and approaches are available for pain management in cats that may be safer than meloxicam for many patients and situations. Gabapentin has become a mainstay of feline pain management, providing analgesic effects for neuropathic and chronic pain without the renal and gastrointestinal risks of NSAIDs. Buprenorphine, an opioid medication, provides effective analgesia for acute and moderate pain and is commonly used in veterinary practice for post-surgical pain when NSAID risks are concerning. The recently approved monoclonal antibody therapy frunevetmab (Solensia) offers a revolutionary option for managing osteoarthritis pain in cats with an excellent safety profile, including in cats with kidney disease.

Other NSAIDs approved for cats in various markets share the same fundamental risks as meloxicam, though individual products may have slightly different safety profiles. Robenacoxib (Onsior) is approved for short-term use in cats in some countries, with some data suggesting a somewhat more favorable safety margin, though caution remains warranted. Regardless of which NSAID is considered, the species-specific feline sensitivity applies, and the same restrictions on duration and patient selection pertain. Switching between different NSAIDs does not eliminate risk and requires appropriate washout periods.

Non-pharmaceutical approaches play an essential role in managing chronic pain conditions like osteoarthritis in cats, often providing meaningful benefit without medication risks. Weight management reduces stress on painful joints and represents one of the most impactful interventions for overweight cats with musculoskeletal pain. Environmental modifications including ramps, steps, low-sided litter boxes, raised food dishes, and soft bedding improve quality of life for mobility-impaired cats. Physical rehabilitation, acupuncture, and cold laser therapy offer additional options for multimodal pain management. Joint supplements containing glucosamine, chondroitin, or omega fatty acids may provide supportive benefit. These approaches can be combined with medications like gabapentin or frunevetmab for comprehensive pain management without NSAID risks.